/ News Archive -

2012

10.4.2012

Alvogen launches introduces Vancomycin in the U.S. market

Alvogen today announced the introduction of Vancomycin Hydrochloride Capsules, USP, an antibacterial indicated to treat infections that include C. difficile-associated diarrhea and enterocolitis caused by Staphylococcus aureus.

23.3.2012

Alvogen teams up with Columbia University

Alvogen has entered into a collaboration with Columbia University and a group if distinguished scientists from all over the world, representing different academic disciplines. Alvogen is one of the official sponsors of the Life Course Project (Longitudinal Investigation for Epigenetic Causes and Outcomes in the Urban and Rural Social Environments).

2011

9.11.2011

Alvogen to address Annual World Generic Medicines Congress

Robert Wessman, Chairman and CEO of Alvogen, will be a keynote speaker at the 4th Annual World Generic Medicines Congress Americas, in Washington DC. His presentation, "Winning Strategies", will be on November 15 at 9:45 AM, at the Westin Georgetown Hotel.

Speakers list also includes Henry Waxman, a member of the US Congress, Diem Nguyen, VP of Commerical Development of Biosimilars at Pfizer and Subir Basak, CEO of Intas Biopharma.

18.8.2011

Alvogen appoints new business leaders in Poland and Croatia

Tomasz Czekala and Jerko Jaksic have been appointed to serve as key business leaders in Poland and Croatia.

10.8.2011

Alvogen launches new products in Romania

Alvogen today announced that its subsidiary, Alvogen Romania, has launched generic versions of three oncology products: exemestane, irinotecan and letrozole.

20.6.2011

Alvogen teams up with MIT Industrial Liaison Program

Alvogen today announced its collaboration with the Massachusetts Institute of Technology (MIT) through its Industrial Liaison Program (ILP). The program is industry's chief guide and gateway to the vast resources at MIT, a world leader in education and research.

14.6.2011

Alvogen CEO recognized as emerging pharma leader

Doug Drysdale, Alvogen’s CEO, has been named one of Pharmaceutical Executive’s emerging pharma leaders for 2011.

Link to the full article

9.3.2011

Alvogen Appoints Peter Keil as a Regional Manager in Asia

Peter Keil is the new regional manager for Alvogen in Asia and will lead the commercial activities for all countries in the region except China and India.

17.2.2011

Alvogen to Present at the Annual World Generic Medicines Congress

Robert Wessman, Executive Chairman of Alvogen will be a keynote speaker at the 5th Annual World Generic Medicines Congress Europe, in London.

14.2.2011

Alvogen Appoints Laurentiu Scheusan as EVP of Sales in Central and Eastern Europe

Scheusan has an outstanding track record in the generic industry after holding senior executive positions with large global generic companies.

9.2.2011

Alvogen and Natco secure first-to-file status on generic version of Tamiflu®

- 180-day marketing exclusivity expected
- U.S. brand sales in excess of US$1 billion
- Complements a fast growing U.S. pipeline of over 70 drugs

26.1.2011

Alvogen Launches Nitroglycerin Transdermal Delivery System

- Nitroglycerin patch includes small patch sizes and RSS barcoding

2010

19.11.2010

Alvogen completes funding for further growth

Alvogen, today announced that it has successfully closed a private placement financing.

8.11.2010

Alvogen launches Clopidogrel in Romania

Alvogen today announced that its subsidiary, Alvogen Romania has launched Clopidogrel (Vatoud 75mg).

14.6.2010

Alvogen opens new R&D center of excellence

Alvogen has opened a new research and development facility aimed at developing first-to-file and complex generic pharmaceutical products, including controlled release pharmaceuticals.

4.5.2010

Alvogen teams up with Orchid in India

Alvogen today announced that it has entered into an agreement with Orchid Chemicals & Pharmaceuticals. Alvogen will market eight high potential oral products from Orchid in the US market, with ...

27.4.2010

Alvogen expands its operations in India

Alvogen Inc. (“Alvogen”), the US-based generic pharmaceuticals company, today announced that it has expanded its operations in India, by establishing own clinical research organization (“CRO”) and...

15.4.2010

Alvogen appoints team of experienced business development leaders

Alvogen Inc, the US-based generic pharmaceutical company, today announces that it has added to its Global Business Development and R&D teams. These appointments will further strengthen Alvogen’s capability to ...

30.3.2010

Alvogen appoints three new top executives

Alvogen Inc. the US-based generic pharmaceutical company, today announces that three new top executives have joined its Executive Board. The new executives have an outstanding track record in the generic industry ...

14.1.2010

Alvogen Announces Expansion in Romania.

Alvogen today announced that it has expanded operations in Eastern Europe and has opened an office in Bucharest, Romania.

2009

22.10.2009

Alvogen acquires research and development capabilities and enters into multi-product development deal with Par Pharmaceutical

As part of the agreement, Alvogen and Par have entered into a multi-year agreement for the development of several high-value, first-to-file generic product opportunities.

29.7.2009

Robert Wessman joins Alvogen

Robert Wessman and Alvogen Group combine to build a leading international generics company

11.5.2009

Alvogen Acquires Today® Sponge Assets

Initial Acquisition Reflects Specialty Generics Company's Focus on
Filling Niche Between Branded Pharmaceuticals and Commoditized Generics.

11.5.2009

Todays® Sponge Returns To Store Shelves

Mayer Laboratories, Inc., a marketer of high-quality contraceptives and the exclusive distributor of the Today Vaginal Contraceptive Sponge for the US, Canada and the EU, announced today that the Today^® Sponge has been re-launched in the United States.